Abstracts tagged "Cardiovascular"

Abstract Number: 1981 • ACR Convergence 2024
Assessing Major Adverse Cardiovascular Events (MACE) Risk in Common Rheumatology Treatments
Manush Sondhi¹, Samina Hayat², Kinza Muzaffar¹ and Sarwat Umer¹, ¹LSU HEALTH SHREVEPORT, Shreveport, LA, ²Louisiana State University Shreveport, Shreveport, LA
Background/Purpose: This study aims to evaluate the risk of major cardiovascular events (MACE) associated with common rheumatology medications.Methods: We conducted a retrospective pharmacovigilance analysis using…
Abstract Number: 2459 • ACR Convergence 2024
Use of Nailfold Capillaroscopy as a Predictor of Cardiovascular Events and Mortality in Systemic Sclerosis
Carlos Valera-Ribera¹, Javier Narvaez-García², Joaquín Lacasa-Molina³, Laura Perea-Galera⁴, Alida Taberner-Cortés³, Paula Andrea Mencio-Viana³, Patricia Leon-Torralba³, Adrián Mayo-Juanatey³, Pablo Andújar-Brazal³, Ignacio Vázquez Gómez⁵, Desamparados Ybáñez-García³, Àngels Martínez-Ferrer⁶, Elia Valls-Pascual⁷, Montserrat Robustillo Villarino⁸ and JUAN JOSE ALEGRE SANCHO³, ¹Hospital Doctor Peset, Valéncia, Comunidad Valenciana, Spain, ²Hospital Universitario de Bellvitge, Barcelona, Spain, ³Hospital Universitario Doctor Peset, Valencia, Spain, ⁴Hospital Universitario Doctor Peset, Valencia, ⁵H. U. Dr. Peset, Valencia, ⁶Hospital Universitario Dr Peset Valéncia, Valéncia, Spain, ⁷Hospital General de Valencia, Valencia, Comunidad Valenciana, Spain, ⁸Hospital Universitario La Plana, Villarreal, Spain
Background/Purpose: Systemic sclerosis (SSc) is a disease with high morbidity and mortality. Nailfold capillaroscopy (NFC) is a widely used method for its diagnosis. Our objective…
Abstract Number: L11 • ACR Convergence 2023
Risk of Cardiovascular Events According to Biological Agent Exposure in Patients with Ankylosing Spondylitis: A Korean Population-based Study
Oh Chan Kwon, Hye Sun Lee, Juyeon Yang, Yong-Beom Park and Min-Chan Park, Yonsei University College of Medicine, Seoul, South Korea
Background/Purpose: Patients with ankylosing spondylitis (AS) have a higher risk of cardiovascular events than controls. Although biological disease-modifying anti-rheumatic drugs (bDMARDs) are efficacious in treating…
Abstract Number: 0236 • ACR Convergence 2023
Treatment-emergent Major Adverse Cardiovascular and Thromboembolic Events Were Infrequent During Pegloticase Therapy: Pooled Clinical Trial Findings
orrin Troum¹, Mai Duong², Katie Obermeyer², Lissa Padnick-Silver² and Brian LaMoreaux², ¹University of Southern California Keck School of Medicine and Providence Saint John's Health Center, Santa Monica, CA, ²Horizon Therapeutics, Deerfield, IL
Background/Purpose: Gout is associated with high comorbidity, including cardiovascular (CV), metabolic, and renal disease,1 with even higher burden in uncontrolled gout patients (pts).2 CV (myocardial…
Abstract Number: 0496 • ACR Convergence 2023
Higher Values of Atherogenic Index of Plasma Are Correlated with Increased Cardiovascular Risk in Patients with Psoriatic Arthritis
Valeria Gonzalez-Gonzalez¹, Iris Colunga², Dionicio A. Galarza-Delgado², José Ramón Azpiri-López², Rosa Arvizu-Rivera³, Jesus Alberto Cardenas-De la Garza⁴, Victor Beltran⁵ and Angel Arias Peralta⁶, ¹Universidad Autónoma de Nuevo León, Monterrey, Mexico, ²Hospital Universitario UANL, Monterrey, Mexico, ³Hospital Universitario "Dr. José Eleuterio Gonzalez", Escobedo, Mexico, ⁴Hospital Universitario "Dr. José Eleuterio González", San Nicolas, Mexico, ⁵Rheumatology Service Hospital Universitario "Dr. José Eleuterio González", Monterrey, Mexico, ⁶Medicine Faculty, Universidad Autonoma De Nuevo Leon, Monterrey, Mexico
Background/Purpose: The atherogenic index of plasma (AIP) is a predictor of atherosclerosis and coronary heart disease. In patients with systemic lupus erythematosus and rheumatoid arthritis,…
Abstract Number: 0703 • ACR Convergence 2023
Cardiovascular Disease-Related Mortality in Primary Systemic Vasculitis
Alicia Rodriguez-Pla, Sierra Pacific Arthritis and Rheumatology Centers, Fresno, CA
Background/Purpose: Cardiovascular disease (CVD) is the leading cause of death in patients with the most common subtypes of primary systemic vasculitides. We aimed to estimate…
Abstract Number: 1116 • ACR Convergence 2023
The Current State of Sodium-Glucose Cotransporter Type 2 Inhibitor Use Among Patients with Gout at a Tertiary Academic Healthcare System
Chio Yokose¹, Baijun Zhou¹, Natalie McCormick¹, Sruthi Tanikella¹, Minna Kohler², Janeth Yinh¹, Yuqing Zhang³ and Hyon K. Choi⁴, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, ⁴Massachusetts General Hospital and Harvard Medical School, Lexington, MA
Background/Purpose: A substantial proportion of gout patients have type 2 diabetes (T2DM), heart failure (HF), and chronic kidney disease (CKD), for which SGLT2i treatment is…
Abstract Number: 1343 • ACR Convergence 2023
Cardiovascular (CV) and Malignancy Events in the Filgotinib Rheumatoid Arthritis (RA) Clinical Development Program up to 8.3 Years
Xavier Mariette¹, Sven Borchmann², Sandrine Aspeslagh³, Jaime Calvo- Alén⁴, Richard Moriggl⁵, Zoltan Szekanecz⁶, Francesco De Leonardis⁷, Nadia Verbruggen⁸, Paul Van Hoek⁹, Marc Schmalzing¹⁰, Andreas Stallmach¹¹, Christina Charles-Schoeman¹², Vijay Rajendran¹³, Christine Rudolph⁹, Chris Watson¹⁴, Yoshiya Tanaka¹⁵ and Ernest Choy¹⁶, ¹Université Paris-Saclay, Le Kremlin-Bicêtre, France, ²Department of Internal Medicine, University of Cologne, Cologne, Germany, ³Department of Medical Oncology, UZ Brussel, Brussels, Belgium, ⁴Rheumatology, Bioaraba Research Unit, Hospital Universitario Araba, Vitoria, Spain, ⁵Institute of Animal Breeding and Genetics, University of Veterinary Medicine, Vienna, Austria, ⁶Division of Rheumatology, University of Debrecen, Debrecen, Hungary, ⁷Medical Affairs, Galapagos GmbH, Basel, Switzerland, ⁸Biostatistics, Galapagos NV, Mechelen, Belgium, ⁹Medical Safety, Galapagos NV, Mechelen, Belgium, ¹⁰University Hospital, Rheumatology/Clinical Immunology, Department of Internal Medicine II, Würzburg, Germany, ¹¹Department of Internal Medicine, Jena University Hospital, Jena, Germany, ¹²UCLA Medical Center, Santa Monica, CA, ¹³Clinical Research, Galapagos NV, Mechelen, Belgium, ¹⁴Medical Affairs, Galapagos Biotech Ltd., Cambridge, United Kingdom, ¹⁵University of Occupational and Environmental Health, Kitakyushu, Japan, ¹⁶Section of Rheumatology, Cardiff University, Cardiff, United Kingdom
Background/Purpose: Filgotinib (FIL) is a Janus kinase (JAK) 1 preferential inhibitor for the treatment of RA. Data from the ORAL Surveillance post-marketing study (NCT02092467) suggest…
Abstract Number: 1806 • ACR Convergence 2023
The Prevalence of Cardiac Sarcoidosis – A Systemic Review and Meta-Analysis
Daming Shao¹, Jiyoung Seo¹, Shaunak Mangeshkar¹, Natalia Nazarenko¹, Stepan Esagian¹, Leonidas Palaiodimos¹ and Damianos Kokkinidis², ¹Albert Einstein College of Medicine/Jacobi Medical Center, Bronx, NY, ²Yale University School of Medicine, New Haven, CT
Background/Purpose: Cardiac sarcoidosis (CS) results from granulomatous infiltrating of the myocardium and manifests as an extended clinical spectrum from silence to conduction disturbances, ventricular tachyarrhythmias,…
Abstract Number: 2145 • ACR Convergence 2023
Patterns of Use, Effectiveness, Persistence and Cardiovascular Risk in Patients with Rheumatic Diseases Treated with Upadacitinib in a Real-world Setting. UPAREAL Study
Alicia Garcia Dorta¹, Andrea Hernández Martín², Cristina Rodríguez Regalado³, Sonia Isis Peña Montelongo⁴, Cristina Martínez González⁵, Elena Naveda-González², Enrique González-Dávila⁶, Jose Federico Diaz-Gonzalez⁷ and maría Vanesa Hernández Hernández⁵, ¹Rheumatology Unit, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ²Rheumatology Unit, Hospital Universitario Dr Negrín, Las Palmas de Gran Canaria, Spain, ³Rheumatology Unit, Hospital Universitario Ntra Sra de la Candelaria, Santa Cruz de Tenerife, Spain, ⁴Rheumatology Unit, Hospital Virgen de la Peña, Fuerteventura, Spain, ⁵Rheumatology Unit, Hospital Universitario de Canarias, San Cristobal de la Laguna, Spain, ⁶Department of Mathematics, Statistics and Operation Reseach La Laguna University, La Laguna, Spain, ⁷Hospital Universitario de Canarias, La Laguna, Spain
Background/Purpose: Based mainly on results from a randomized clinical trial (RCT) in rheumatoid arthritis (RA) patients (ORAL Surveillance), major regulatory agencies have concluded that JAK…
Abstract Number: 0239 • ACR Convergence 2023
Incidence and Prevalence of Cardiovascular and Metabolic Diseases Following Gout Diagnosis in the United Kingdom Using the THIN Database
Michael Garshick¹, Haridarshan Patel², ada Kumar², Brian LaMoreaux², Lissa Padnick-Silver², Louis Dron³, Vinusha Kalatharan³, Vivek Verma³ and Michael Pillinger⁴, ¹NYU School of Medicine/NYU Langone Medical Center, New York, NY, ²Horizon Therapeutics, Deerfield, IL, ³Cytel Canada Inc., Vancouver, BC, Canada, ⁴New York University Grossman School of Medicine, New York, NY
Background/Purpose: Gout is a common inflammatory arthropathy characterized by pain, joint swelling, and monosodium urate crystal deposits in joints, organs, and soft tissues.1 While gout…
Abstract Number: 0498 • ACR Convergence 2023
Biological Therapies for Psoriasis and Psoriatic Arthritis- effects on Future Risk Development of Major Adverse Cardiovascular Events (MACE)
Arad Dotan¹, Niv Ben-Shabbat¹, Abdulla watad², Dennis McGonagle³ and Howard AMITAL², ¹Department of Medicine 'B'. Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Israel, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel, ²Sheba Medical Center, Ramat Gan, Israel, ³Leeds Biomedical Research Centre, University of Leeds, Leeds, United Kingdom
Background/Purpose: Major adverse cardiovascular events (MACE) are known comorbidities and consequences of psoriasis (PsO) and psoriasis arthritis (PsA). Previous studies underlined the potential of immunomodulatory…
Abstract Number: 0722 • ACR Convergence 2023
Acute Cardiovascular Events in Autoimmune Rheumatic Disease Pregnancies
Rashmi Dhital¹, Rebecca Baer², Monica Guma², Kenneth Kalunian², Accelerating Medicines Partnership Program RA SLE Network³ and Christina Chambers², ¹UC San Diego, San Diego, CA, ²University of California San Diego, La Jolla, CA, ³Cedars-Sinai Medical Center, Los Angeles, CA
Background/Purpose: Cardiovascular diseases (CVDs) complicate 1-4% of pregnancies. Autoimmune rheumatic diseases (ARDs) are associated with a 1.5 to 3-fold higher CVD risk. Similarly, antiphospholipid syndrome…
Abstract Number: 1117 • ACR Convergence 2023
Serum Urate Change Among Gout Patients Initiating Sodium-Glucose Cotransporter Type 2 Inhibitors (SGLT2i) vs. Sulfonylureas: A Comparative Effectiveness Analysis
Chio Yokose¹, Gregory Challener², Baijun Zhou², Natalie McCormick², Sruthi Tanikella², Kila Panchot², Minna Kohler³, Janeth Yinh², Yuqing Zhang⁴, David Bates⁵, James Januzzi², Meghan Sise², Deborah Wexler² and Hyon K. Choi⁶, ¹Massachusetts General Hospital, Waltham, MA, ²Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, ⁵Brigham and Women's Hospital, Boston, MA, ⁶Massachusetts General Hospital and Harvard Medical School, Lexington, MA
Background/Purpose: Sodium-glucose cotransporter type 2 inhibitors (SGLT2i) are currently indicated as second-line therapy for type 2 diabetes and are also approved for the treatment of…
Abstract Number: 1399 • ACR Convergence 2023
Trends in Proportionate Cardiovascular Mortality in Patients with Ankylosing Spondylitis in the Era of Biologic Therapies: Analysis of US Death Certificate Data
Ansaam Daoud¹, Sadeer Al-Kindi² and Marina Nighat Magrey³, ¹University Hospitals, Case Western Reserve University, Akron, OH, ²Case Western Reserve University/University Hospitals, Cleveland, OH, ³Case Western Reserve University, University Hospitals, Cleveland, OH
Background/Purpose: Ankylosing Spondylitis (AS) is associated with an increased risk of cardiovascular disease, partly due to systemic inflammation, and an increased risk of vascular mortality.…

« Previous Page
1
…
6
7
8
9
10
…
31
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].